NEW YORK – Leapfrog Bio on Wednesday said it will move on to a Phase II trial of its bromodomain and extra-terminal domain (BET) protein inhibitor LFB-190 in lung, colon, and bladder cancer after ...

Impact-focused private equity (PE) firm LeapFrog Investments closed its fourth fund (Fund IV), raising $1.02 billion in commitments and designated co-investments and surpassing its initial target of ...